AMICUS THERAPEUTICS INC (FOLD) Stock Fundamental Analysis
USA - NASDAQ:FOLD - US03152W1099 - Common Stock
9.005 USD
-0.18 (-2.01%)
FOLD gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 534 industry peers in the Biotechnology industry. There are concerns on the financial health of FOLD while its profitability can be described as average. FOLD is growing strongly while it is still valued neutral. This is a good combination!
1. Profitability
1.1 Basic Checks
FOLD had positive earnings in the past year.
In the past year FOLD has reported a negative cash flow from operations.
FOLD had negative earnings in each of the past 5 years.
FOLD had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
FOLD has a better Return On Assets (-4.67%) than 87.45% of its industry peers.
Looking at the Return On Equity, with a value of -18.65%, FOLD belongs to the top of the industry, outperforming 85.58% of the companies in the same industry.
FOLD has a better Return On Invested Capital (3.06%) than 91.01% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -4.67% | ||
| ROE | -18.65% | ||
| ROIC | 3.06% |
ROA(3y)-19.77%
ROA(5y)-23.64%
ROE(3y)-105.3%
ROE(5y)-98.82%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Operating Margin, with a value of 4.39%, FOLD belongs to the top of the industry, outperforming 90.45% of the companies in the same industry.
With an excellent Gross Margin value of 90.37%, FOLD belongs to the best of the industry, outperforming 91.76% of the companies in the same industry.
In the last couple of years the Gross Margin of FOLD has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 4.39% | ||
| PM (TTM) | N/A | ||
| GM | 90.37% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.48%
GM growth 5Y0.45%
2. Health
2.1 Basic Checks
FOLD has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
The number of shares outstanding for FOLD has been increased compared to 1 year ago.
Compared to 5 years ago, FOLD has more shares outstanding
FOLD has a better debt/assets ratio than last year.
2.2 Solvency
FOLD has an Altman-Z score of -0.66. This is a bad value and indicates that FOLD is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -0.66, FOLD perfoms like the industry average, outperforming 57.30% of the companies in the same industry.
FOLD has a Debt/Equity ratio of 1.92. This is a high value indicating a heavy dependency on external financing.
FOLD has a Debt to Equity ratio of 1.92. This is in the lower half of the industry: FOLD underperforms 79.78% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.92 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.66 |
ROIC/WACC0.33
WACC9.38%
2.3 Liquidity
FOLD has a Current Ratio of 3.21. This indicates that FOLD is financially healthy and has no problem in meeting its short term obligations.
FOLD has a Current ratio of 3.21. This is in the lower half of the industry: FOLD underperforms 62.17% of its industry peers.
A Quick Ratio of 2.29 indicates that FOLD has no problem at all paying its short term obligations.
FOLD has a worse Quick ratio (2.29) than 69.29% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.21 | ||
| Quick Ratio | 2.29 |
3. Growth
3.1 Past
FOLD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 123.53%, which is quite impressive.
Looking at the last year, FOLD shows a very strong growth in Revenue. The Revenue has grown by 32.29%.
FOLD shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 23.73% yearly.
EPS 1Y (TTM)123.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%950%
Revenue 1Y (TTM)32.29%
Revenue growth 3Y20.03%
Revenue growth 5Y23.73%
Sales Q2Q%19.46%
3.2 Future
Based on estimates for the next years, FOLD will show a very strong growth in Earnings Per Share. The EPS will grow by 70.90% on average per year.
Based on estimates for the next years, FOLD will show a very strong growth in Revenue. The Revenue will grow by 20.44% on average per year.
EPS Next Y73.29%
EPS Next 2Y89.17%
EPS Next 3Y71.81%
EPS Next 5Y70.9%
Revenue Next Year19.05%
Revenue Next 2Y20.13%
Revenue Next 3Y19.68%
Revenue Next 5Y20.44%
3.3 Evolution
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 112.56, which means the current valuation is very expensive for FOLD.
Compared to the rest of the industry, the Price/Earnings ratio of FOLD indicates a rather cheap valuation: FOLD is cheaper than 90.26% of the companies listed in the same industry.
The average S&P500 Price/Earnings ratio is at 26.13. FOLD is valued rather expensively when compared to this.
Based on the Price/Forward Earnings ratio of 31.69, the valuation of FOLD can be described as expensive.
Based on the Price/Forward Earnings ratio, FOLD is valued cheaper than 90.64% of the companies in the same industry.
FOLD is valuated rather expensively when we compare the Price/Forward Earnings ratio to 22.35, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 112.56 | ||
| Fwd PE | 31.69 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of FOLD indicates a rather cheap valuation: FOLD is cheaper than 90.07% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 88.64 |
4.3 Compensation for Growth
The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
A more expensive valuation may be justified as FOLD's earnings are expected to grow with 71.81% in the coming years.
PEG (NY)1.54
PEG (5Y)N/A
EPS Next 2Y89.17%
EPS Next 3Y71.81%
5. Dividend
5.1 Amount
FOLD does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:FOLD (11/6/2025, 12:40:07 PM)
9.005
-0.18 (-2.01%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners101.58%
Inst Owner Change-0.31%
Ins Owners0.6%
Ins Owner Change2.67%
Market Cap2.78B
Revenue(TTM)528.29M
Net Income(TTM)-38096000
Analysts84.71
Price Target16.32 (81.23%)
Short Float %6.4%
Short Ratio4.02
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)7.84%
Min EPS beat(2)-26.06%
Max EPS beat(2)41.73%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-3.25%
Min Revenue beat(2)-9.62%
Max Revenue beat(2)3.12%
Revenue beat(4)2
Avg Revenue beat(4)-1.2%
Min Revenue beat(4)-9.62%
Max Revenue beat(4)3.12%
Revenue beat(8)4
Avg Revenue beat(8)-0.78%
Revenue beat(12)7
Avg Revenue beat(12)-0.51%
Revenue beat(16)8
Avg Revenue beat(16)-1.25%
PT rev (1m)0.63%
PT rev (3m)2.13%
EPS NQ rev (1m)-0.46%
EPS NQ rev (3m)92.85%
EPS NY rev (1m)-5.2%
EPS NY rev (3m)41.41%
Revenue NQ rev (1m)0.27%
Revenue NQ rev (3m)0.85%
Revenue NY rev (1m)0.07%
Revenue NY rev (3m)1.05%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 112.56 | ||
| Fwd PE | 31.69 | ||
| P/S | 4.86 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 13.59 | ||
| P/tB | N/A | ||
| EV/EBITDA | 88.64 |
EPS(TTM)0.08
EY0.89%
EPS(NY)0.28
Fwd EY3.16%
FCF(TTM)-0.16
FCFYN/A
OCF(TTM)-0.15
OCFYN/A
SpS1.85
BVpS0.66
TBVpS-0.03
PEG (NY)1.54
PEG (5Y)N/A
Graham Number1.09
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -4.67% | ||
| ROE | -18.65% | ||
| ROCE | 3.87% | ||
| ROIC | 3.06% | ||
| ROICexc | 4.75% | ||
| ROICexgc | 9.73% | ||
| OM | 4.39% | ||
| PM (TTM) | N/A | ||
| GM | 90.37% | ||
| FCFM | N/A |
ROA(3y)-19.77%
ROA(5y)-23.64%
ROE(3y)-105.3%
ROE(5y)-98.82%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.48%
GM growth 5Y0.45%
F-Score5
Asset Turnover0.7
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.92 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 11.88 | ||
| Cap/Depr | 41.25% | ||
| Cap/Sales | 0.57% | ||
| Interest Coverage | 0.44 | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.21 | ||
| Quick Ratio | 2.29 | ||
| Altman-Z | -0.66 |
F-Score5
WACC9.38%
ROIC/WACC0.33
Cap/Depr(3y)68.89%
Cap/Depr(5y)61.13%
Cap/Sales(3y)1.23%
Cap/Sales(5y)1.24%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)123.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%950%
EPS Next Y73.29%
EPS Next 2Y89.17%
EPS Next 3Y71.81%
EPS Next 5Y70.9%
Revenue 1Y (TTM)32.29%
Revenue growth 3Y20.03%
Revenue growth 5Y23.73%
Sales Q2Q%19.46%
Revenue Next Year19.05%
Revenue Next 2Y20.13%
Revenue Next 3Y19.68%
Revenue Next 5Y20.44%
EBIT growth 1Y191.42%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year134.62%
EBIT Next 3Y105.52%
EBIT Next 5YN/A
FCF growth 1Y63.3%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y63.94%
OCF growth 3YN/A
OCF growth 5YN/A
AMICUS THERAPEUTICS INC / FOLD FAQ
What is the fundamental rating for FOLD stock?
ChartMill assigns a fundamental rating of 4 / 10 to FOLD.
What is the valuation status of AMICUS THERAPEUTICS INC (FOLD) stock?
ChartMill assigns a valuation rating of 4 / 10 to AMICUS THERAPEUTICS INC (FOLD). This can be considered as Fairly Valued.
What is the profitability of FOLD stock?
AMICUS THERAPEUTICS INC (FOLD) has a profitability rating of 4 / 10.
What are the PE and PB ratios of AMICUS THERAPEUTICS INC (FOLD) stock?
The Price/Earnings (PE) ratio for AMICUS THERAPEUTICS INC (FOLD) is 112.56 and the Price/Book (PB) ratio is 13.59.
Can you provide the financial health for FOLD stock?
The financial health rating of AMICUS THERAPEUTICS INC (FOLD) is 3 / 10.